Moderna's mRNA-based vaccine against RSV (respiratory syncytial (sin-SISH-uhl) virus) was effective at preventing disease in older adults, according to preliminary, top-line results of an ongoing phase III clinical trial the company announced Tuesday.Moderna said it will now seek regulatory approval for the vaccine in the first half of this year.
#years #development #researchers #approximately #disease-control #press-release #demonstration #young-children #older-adults #pharmaceutical-companies
[
add
]
[
|
|
...
]